Clinical trial · no report yet · Phase 3
AHOD2131
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
- NCT05675410 ↗
- Recruiting
- National Cancer Institute (NCI)
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 7 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
- Phase
- Phase 3
- Status
- Recruiting
- Conditions
- Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
- Interventions
- Biospecimen Collection; Bleomycin Sulfate; Brentuximab Vedotin; Computed Tomography; Cyclophosphamide; Dacarbazine; Doxorubicin Hydrochloride; Etoposide; Etoposide Phosphate; Fludeoxyglucose F-18; Involved-site Radiation Therapy; Magnetic Resonance Imaging; Nivolumab; Positron Emission Tomography; Prednisolone; Prednisone; Procarbazine Hydrochloride; Questionnaire Administration; Vinblastine Sulfate; Vincristine Sulfate
- Arms
- Arm A (ABVD) · Active comparator
- Arm B (ABVD, brentuximab vedotin, nivolumab) · Experimental
- Arm C (ABVD, eBEACOPP or eBPDac, ISRT) · Experimental
- Arm D (ABVD, brentuximab vedotin, nivolumab, ISRT) · Experimental
- Arm E (ABVD, AVD) · Experimental
- Arm F (ABVD, brentuximab vedotin, nivolumab) · Experimental
- Arm G (ABVD, eBEACOPP or eBPDac, ISRT) · Experimental
- Arm H (ABVD, brentuximab vedotin, nivolumab, ISRT) · Experimental
- Enrollment
- 1,875 (estimated)
- Primary outcomes
- Progression-free survival (PFS) in rapid early responder (RER) patients
- PFS in slow-early responder (SER) patients
- Sponsor
- National Cancer Institute (NCI)
- Start
- May 11, 2023
- Primary completion
- Apr 28, 2031 (estimated)
- Results posted
- No
- Registry record
- NCT05675410 · updated Oct 16, 2026
Publications
linked from the registry- Castellino SM, Giulino-Roth L, Harker-Murray P, Kahn JM, Forlenza C, Cho S, Hoppe B, Parsons SK, Kelly KM; COG Hodgkin Lymphoma Committee. Children's Oncology Group's 2023 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer. 2023 Sep;70 Suppl 6(Suppl 6):e30580. doi: 10.1002/pbc.30580. Epub 2023 Jul 28. PubMed 37505794